Posted by Michael Wonder on 14 Jul 2022
BeiGene provides regulatory update on the U.S. biologics license application for PD-1 inhibitor tislelizumab in second-line oesophageal squamous cell carcinoma
14 July 2022 - Due to COVID travel restrictions, inspections could not be completed during review period.
BeiGene today announced that the U.S. FDA has deferred action on the biologics license application for tislelizumab as a second-line treatment for patients with unresectable or metastatic oesophageal squamous cell carcinoma.
